Neurokinin‐1 receptor antagonists for prevention of chemotherapy‐related nausea and vomiting in adults
Appendices
Appendix 1. Search strategy
#1: Randomized clinical trial
#2: Controlled clinical trial
#3: Random allocation
#4: Double blind method
#5: Single blind method
#6: Clin* trial*
#7: Placebo
#8: Random*
#9: Research design
#10: Comparative study
#11: Prospective stud*
#12: Cross‐over
#13: Crossover
#14: Factorial
#15: Systematic review
#16: Metaanalysis
#17: Meta‐analysis
#18: Metaan*
#19: #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18
#20: Nausea
#21: Vomiting
#22: Emesis
#23: #20 OR #21 OR #22
#24: Acute
#25: Delayed
#26: #24 OR #25
#27: #23 AND #26
#28: Neurokinin‐1
#29: Neurokinin‐1 receptor antagonist*
#30: Neurokinin‐1 inhibitor*
#31: Substance P
#32: MK‐869
#33: MK0869
#34: L‐758,298
#35: L‐754,030
#36: Aprepitant
#37: Emend (registered)
#38: CP99,994
#37: CJ‐11,974
#38: GR 205171
#39: Ezlopitant
#40: Casopitant
#41: #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 or #39 or #40
#42: #19 AND #27 AND #41
| Emetogenicity | Drug |
| HIGH (> 90%) | Cisplatin |
| Dacarbazine | |
| Mechloretamine | |
| Streptozocin | |
| Cyclophosphamide (> 1500 mg/m2) | |
| Actinomycin‐D | |
| Carmustine | |
| MODERATE (30 to 90%) | Carboplatin |
| Oxaliplatin | |
| Cyclophosphamide (<1500 mg/m2) | |
| Lomustine (CCNU) | |
| Daunorubicin | |
| Doxorubicin | |
| Epirubicin | |
| Idarubicin | |
| ARA‐C (Arabinoside cytosine) | |
| Ifosfamide | |
| Irinotecan | |
| LOW (10 to 30%) | Paclitaxel |
| Docetaxel | |
| Mitoxantrone | |
| Topotecan | |
| Etoposide | |
| Pemetrexed | |
| Methotrexate | |
| Mitomycin | |
| Gemcitabine | |
| Cytarabine (< 1000 mg/m2) | |
| Fluorouracil | |
| Bortezomib | |
| Cetuximab | |
| Trastuzumab | |
| Rituximab | |
| Bevacizumab | |
| Busulfan | |
| 2‐chlorodeoxyadenosine | |
| Fludarabine | |
| Vinblastine | |
| Vincristine | |
| Vinorelbine | |
| Bleomycin |
